Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

about

A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.Canakinumab for the treatment of TNF-receptor associated periodic syndrome.

P2860

Q38633441-E2C0A22D-3B83-4925-ACBD-D92355F8DF76 Q38814103-A1982AE7-4C54-4C6C-9F4D-65204F998B70

P2860

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

Item

http://www.wikidata.org/entity/Q38255582

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

@en

type

Item

label

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

@en

prefLabel

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

@en

P1476

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

@en

P2093

Alexei A Grom

http://www.w3.org/2001/XMLSchema#string

P2860

The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening a

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Use of canakinumab in the cryopyrin-associated periodic syndrome.

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.

P304

1427-1435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2014.965149

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25269376

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

about

P2860

P2860

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921